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Abstract microRNAs are endogenous noncoding RNAs
that are implicated in gene regulation. More recently,
miRNAs have been shown to play a pivotal role in multiple
cellular processes that interfere with tumorigenesis. Here
we summarize the essential role of microRNAs for human
cancer with special focus on malignant melanoma and the
promising perspectives for cancer therapies.








snRNA small nuclear RNA
Introduction
Malignant melanoma is characterized as a malignant
neoplasm that is initially composed of proliferation of
aberrant melanocytes. These atypical melanocytes have
distinct defects in cellular processes that include cell cycle
regulation, cell signalling, cell adhesion, cell differentiation,
and cell death (Bartel 2004). Furthermore, malignant
melanoma is one of the most aggressive cancer types in
humans with propensity for distant metastasis behavior, and
metastasized melanoma is resistant to many of the available
therapies. At present, dacarbazine has the best efficacy
with a response rate ranging from 5% to 29% and a short
4-month median response duration (Blower et al. 2007).
Notably, the incidence of melanoma is progressively
increasing in the past decades (1 in 74 Americans will
develop melanoma during his lifetime). Moreover, death
that is caused by malignant melanoma is also increasing, as
its mortality rate has risen by 2% annually since 1960
(Bartel 2004; Eigentler et al. 2003).
The limited success of available treatments underlines the
needs to develop new therapeutic and preventive approaches
for malignant metastasized melanoma (Grabacka et al. 2006).
Therefore, in recent years, new molecular therapy analyzes
the possibility of miRNA involvement in malignant mela-
noma treatment. Molecular biology studies have long
reported the existence of noncoding RNAs in different
organisms, among which miRNAs represent a new highly
impressive class to be studied in tumor biology field.
microRNA, which is a short noncoding negative regulator
of gene expression, interacts with messenger RNA (mRNA)
and could be intimately involved in the development of
cancer (Halaban et al. 2009).
Previous studies have demonstrated an association
between tumor incidence and gene mutations, while recent
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studies have reported that the expression of these genes
might be modified by deregulated miRNAs without any
concomitant alteration or mutation in gene sequences.
Changes in the sequence of miRNA or in the miRNA
target region of a transcript might also have a major
impact on posttranscriptional regulation (Hammond 2006).
Therefore, it remains to be investigated to what extent
miRNAs expression in malignant melanoma cell lines
could affect tumor development, metastasis, and response
to treatment.
microRNA biogenesis
miRNAs are generally 18 to 25 nt long. They were first
described in the early 1990s in the worm Caenorhabditis
elegans as regulators of development and differentiation.
miRNAs are produced from either their own genes or from
introns by RNA polymerase II, which catalyzes the
transcription of DNA to synthesize precursors of mRNA
and most snRNA and microRNA (Hammond 2006;
Horwich and Zamore 2008) (Fig. 1).
MiRNAs are initially expressed as primary miRNA (pri-
miRNA), which are apparently transcribed by RNA
polymerase II, in the cell nucleus, and include a cap and
poly(A) tail. The miRNA portion of the pri-miRNA
transcript likely forms a hairpin with signals for dsRNA-
specific nuclease cleavage (Horwich and Zamore 2008).
This processing is performed in animals by a protein
complex known as the microprocessor complex, consisting
of the dsRNA-specific ribonuclease Drosha that digests the
pri-miRNA in the nucleus to release hairpin and the dsRNA
binding protein Pasha. Then these pre-miRNAs of approx-
imately 70 nt are processed to mature miRNAs in the
cytoplasm by interaction with the endonuclease Dicer, a
member of the RNaseIII, which also initiates the formation
of the RNA-induced silencing complex (RISC). To control
the translation of target mRNAs, the double-strand RNA
produced by Dicer proceed to strand separate, and the
single-strand mature miRNA must associate with the RISC.
This complex is responsible for the gene silencing observed
due to miRNA expression (Igoucheva and Alexeev 2009).
microRNA function and mechanism of action
microRNAs are short noncoding RNAs that act as
endogenous regulators of hundreds of target genes. In fact,
these miRNAs may influence cellular processes such as
development, cell proliferation, apoptosis, survival, and
differentiation by controlling the expression levels of
hundreds of mRNA species (Horwich and Zamore 2008;
Kurihara and Watanabe 2004). The fact that remarkably
small numbers of nucleotides are required for miRNA-
directed target repression suggest that each miRNA can
regulate numerous mRNAs, and up to one third of human
mRNA are predicted to serve as a potential miRNA target
(Lehmann et al. 2008).
Recently, it has been shown that miRNAs are well
recognized as gene regulators via binding to the 3’-
untranslated regions of their respective targets protein
coding transcript. Additionally, miRNA can use a mecha-
nism of gene regulation termed translational repression,
which does not result in the degradation of their mRNA
Fig. 1 miRNA biogenesis:
miRNAs originate in the nucleus
as hairpin precursors and then
are processed by the RNaseIII
enzymes, Drosha and Dicer, to
yield double-stranded RNA.
One strand is selected to func-
tion as mature miRNA and
loaded into the RISC, while
another strand is degraded. Then
miRNA binds imperfectly with
its target mRNA in animal,
whereas it binds with perfect
complementarity in plants,
resulting in mRNA translational
repression
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targets (Halaban et al. 2009; Kurihara and Watanabe 2004).
These miRNAs act by binding imperfectly within the 3’
(untranslated regions [UTRs]) of their mRNA targets,
inducing concomitant repression of their translation. miR-
NAs that use this mechanism are able to reduce the protein
levels of their target genes, while the mRNA levels are
not affected. However, in plants, miRNAs have perfect
sequence complementarity with mRNA targets, which lead
to irreversible endonucleolytic cleavage and degradation of
the mRNA. The degradation pathway and the translational
repression pathway both result in posttranscriptional gene
silencing (Kurihara and Watanabe 2004).
The tissue-restricted expression of many miRNAs
suggests that they might be involved in the differentiation
and development in a cell-type and tissue-specific manner.
For example, miR-1 and miR-133 have a role in the
development of the heart and skeletal muscle, while miR-
181 is playing an essential role in B-cell-progenitor
determination and hematopoietic differentiation (Liu et al.
2008; Lewis et al. 2005).
Expression profile of microRNA in cancer
Despite a poor characterization of the biological functions
and the target genes of miRNAs, it has been confirmed that
their expression is changing in tumorigenesis. They are
strongly involved in differentiation and development, two
main features that are deregulated in cancer (Halaban et al.
2009; Lujambio et al. 2008). Additionally, the human
genome contains up to 1000 miRNA, of which more than
300 miRNA have been identified (Liu et al. 2008; Ma et al.
2007). Recent studies have shown that the expression of
miRNAs affects the activities of their targeted mRNA
encoding proteins. These target mRNAs may have onco-
genic or tumor suppressor functions. As a consequence, the
cancer-related functions of miRNAs frequently depend on
the biological properties of their target genes (Kurihara and
Watanabe 2004).
Recently, it has been demonstrated that microRNAs that
are up-regulated in tumors and whose targets are tumor
suppressor genes might be considered as oncogenes, as the
overexpression of these miRNAs down-regulates the level
of tumor suppress proteins. Conversely, the miRNAs that
are down-regulated in cancer and whose target are
oncogenes are classified as tumor suppressors as summa-
rized in Table 1 (Halaban et al. 2009; Lujambio et al. 2008).
For example, miRNAs such as miR-124a has been found to
be down-regulated in colon, breast, and lung carcinoma cell
lines, suggesting that it can act as tumor suppressor gene.
These data convincingly show that normal miRNA expres-
sion is essential for proper development and differentiation,
and abnormal cell proliferation and differentiation, which
are the hallmark of human cancers, are associated with
aberrant miRNA expression profile (Lujambio et al. 2008).
Accumulating evidence is showing that miRNA expres-
sion might be affected by epigenetic mechanisms such as
DNA methylation and histone modifications. Moreover, it
has been shown that alterations in the expression of
miRNAs may be achieved by treatment with epigenetic
modulator drugs. For example, let-7a-3 locus, which is
involved in lung adenocarcinoma and controls the activity
of the human oncogene RAS, is generally hypomethylated,
and its expression can be epigenetically modulated
(Kurihara and Watanabe 2004; Lujambio et al. 2008). In
contrast, mi124a3, mir-9-1, and mir-152 are hypermethy-
lated in 34% to 86% of all primary human breast cancers
(Ma et al. 2009). Similarly, miR-127, whose target gene is
BCL6, is found to be remarkably up-regulated in cancer
cell lines after treatment with 5-aza-2’-deoxycytidine, a
potent DNA methylation inhibitor, and 4-phenylbutyric
acid, a histone deacetylase inhibitor (Seike 2009).
Signature of microRNA in human cancer metastasis
The metastatic process associates with the capacity of
tumor cells to invade neighboring tissues, enter the
Table 1 Tumor suppressor and oncogenic miRNAs and their target
genes: The biological role of individual miRNA is correlated to the
function of its target gene. IRS insulin receptor substrate-1 (oncogene),
AT1R angiotensin II type 1 receptor, which is responsible for the activity
of the main effector hormone, LATS2 serine/threonine-protein kinase
(which is involved in P53 function), HES1 hairy and enhancer of split
(tumor suppressor), E2F1 transcription factor (plays a crucial role in the
control of cell cycle and action of tumor suppressor proteins)
Tumour suppressor miRNA Target gene Reference Oncogenic miRNA Target gene Reference
Let-7 oncogeneRAS Lujambio et al. 2008 miR-372 P53 Ma et al. 2007
miR-17-5p c-Myc Ma et al. 2007 miR-373 LATS2 Lujambio et al. 2008
miR-20a c-Myc Ma et al. 2007 miR-155 AT1R Lujambio et al. 2008
miR-126 IRS-1 Saito et al. 2009 miR-9-1 HES1 Ma et al. 2007
miR-15a BCL-2 Lujambio et al. 2008 miR-17-92 E2F1 Liu et al. 2008
miR-16 BCL-2 Lujambio et al. 2008 miR-221 P27 Rigel and Carucci 2000
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systemic circulation, reside in distant capillaries, and
translocate into surrounding tissues. Most importantly,
metastasis is responsible for 90% of mortality in solid
tumors. It has been reported that aberrant expression of
miRNAs that regulate tumor suppressor or oncogenes not
only plays an essential role in the development of human
cancer, but also associates with the metastatic behavior of
tumors (Meng et al. 2006).
Three metastasis-promotingmiRNAs have been described:
miR10b, miR-373, and miR-529-c. In contrast, other miR-
NAs such as miR-126 and miR-335 inhibit metastatic process
(Molnára et al. 2008).
miR-10b has been reported to indirectly activate the
prometastatic gene RHOC by suppressing homeobox D10
(HOXD10), thus, leading to tumor invasion and metastasis.
This miRNA is up-regulated exclusively in metastatic cells
(Si et al. 2006)
Additionally, miR-373 can also promote tumor invasion
and metastasis, at least in part by regulating the gene CD44,
which is involved in cell–cell interactions, cell adhesion,
and migration. For example, analysis of normal/tumor
breast samples has shown an up-regulation of miR-373 in
cancer, in particular, in samples exhibiting lymph node
metastasis (Molnára et al. 2008). However, miR-335 works
as metastasis suppressor by inhibiting certain genes that
are associated with human metastasis, particularly the
oncogene SOX4 and tenascin C, an extracellular matrix
component. Interestingly, these remarkable studies suggest
the potent role of miRNAs as stimulators and inhibitors of
metastasis and identify several target genes involved in
cell's metastatic capacity; these data support the molecular
link between miRNA deregulation and a specific tumor
behavior and exert the possibility of using miRNAs within
therapeutic approaches for the prevention of tumor metas-
tasis (Meng et al. 2006; Molnára et al. 2008).
microRNA expression in melanoma
There is a lack of studies about the role of microRNA in the
development and progression of melanoma. Most impor-
tantly, the comparison of normal human epidermal mela-
nocytes with established melanoma cell lines reports that a
set of miRNAs can play a role in malignant melanoma
transformation and in the progression and metastasis of the
tumor (Mueller et al. 2009). One of these studies analyzed
283 known human miRNA gene in 227 human ovarian
cancers, breast cancers, and melanoma samples and
reported that 86% of melanoma cell lines have alteration
in genomic loci containing miRNA genes (Ma et al. 2007).
Further studies, which analyzed miRNAs that were differ-
entially expressed among six tissue groups (CNS, colon,
leukemia, ovarian, renal and melanoma), showed that
expression profile of mir-141, mir-147, mir-192, and mir-
335 might provide a useful tool to predict malignant
melanoma development, because of their differential expres-
sion in melanoma tissue when compared to tissue group
(Negrini and Adrian Calin 2008).
The comparison of the miRNAs expression profiles in
melanocytes with that in melanoma cells identified 49
miRNAs, which are up-regulated tenfold in primary
melanoma cell lines, and 14 miRNAs, which are down-
regulated only by threefold. On the other hand, to
investigate miRNAs that might be associated with meta-
static melanoma, it has been reported that 11 miRNAs are
up-regulated and 2 miRNAs are down-regulated in metas-
tasized melanoma cell lines compared with primary
melanoma cell lines (Mueller et al. 2009; Negrini and
Adrian Calin 2008).
Another study demonstrated down-regulation of let-7
family members in primary cutaneous melanoma compared
with benign nevi (Rigel and Carucci 2000).
This miRNA was previously reported to be involved in
tumor invasion and metastasis by suppressing the p53
pathway and cooperating with oncogenic RAS to induce
cellular transformation (Saito et al. 2006; Rothhammer and
Bosserhoff 2007). Therefore, the differential expression of
some miRNAs in primary malignant melanoma and metas-
tasized melanoma cells in comparison to benign melanocytes
opens new horizons in the understanding of the pathogenesis
and prognosis of malignant melanoma on basis of miRNA
expression profile (Lujambio et al. 2008; Satzger et al. 2009).
Normalizing miRNAs expression in cancer therapy
Since deregulated miRNAs expression has been reported in
many types of human cancer and as miRNA expression has
been observed to affect the activities of targeted mRNA
encoding proteins that have oncogenic or tumor suppressor
functions, an exciting new area of research involves
correcting miRNA expression (Ma et al. 2007; Suárez and
Sessa 2009).
Normalizing the expression of down-regulated miRNAs
or inhibition of overexpressed miRNAs may contribute to
rebalanced expression of large genes implicated in
oncogenesis and tumor progression. For this reason,
targeting of miRNAs might provide an important thera-
peutic strategy for human cancer (Lujambio et al. 2008;
Ma et al. 2007)
Inhibition of overexpressed miRNAs has been achieved
by the intervention of anti-miRNA oligonucleotides (AMOs),
which are complementary to the miRNAs, while the induction
of down-regulated miRNAs might be performed by using
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expression systems that use viral or liposomal delivery
systems for the vectors (Suárez and Sessa 2009; Zhang
et al. 2007).
miRNAs have been speculated to play a potential role in
sensitivity or resistance to specific drugs. In this filed, one
study found that the inhibition of miRNA-21 using antisense
oligonucleotides enhanced growth inhibition of MCF7
cells by topotecan by approximately 40% (Voorhoeve et al.
2006). Similar results have been found in lung cancer cells
and cholangiocytes cell lines when treated with AG1478
and gemcitabine, respectively (Wurdinger and Costa 2006;
Zhang et al. 2006).
In summary, understanding the miRNA signature in
human biology including their expression profile and their
target genes may eventually provide critical information for
an understanding of tumorigenesis and metastasis and
support the possibility of developing new technologies in
the treatment of human malignancies.
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